RxDoctor Payments Data

Cynthia Sloan, DO

Neurology · Wichita Falls, TXNPI 1235117821

Payments from drug & device makers

$31,823in general payments, 2019–2025

Across 187 payments — averaging $170.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$18K
  • Livanova USA, Inc.$11K
  • Medtronic$529
  • EMD Serono, Inc.$430
  • Teva Pharmaceuticals USA, Inc.$346
  • UCB, Inc.$238
  • plus $883 from 17 others

What the payments were for

  • Speaking & faculty fees$24,04276%
  • Travel & lodging$1,7736%
  • Food & beverage$5,99019%
  • Education$180%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$31,823 in reported general payments places this provider in the 80th percentile of 1,246 neurology providers in Texas.

See all neurology providers in Texas

Medicare billing

Part B allowed, 2024
$143,902
Medicare patients
352
Services billed
1,154

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate15$170,022
Avonex (4 Pack)Interferon Beta-1a14$108,405
Aimovig AutoinjectorErenumab-Aooe43$34,774
Trokendi XrTopiramate12$29,614
NuedextaDextromethorphan Hbr/Quinidine25$29,574
UbrelvyUbrogepant24$29,030
Glatiramer Acetate13$18,002
QuliptaAtogepant12$13,186
Levetiracetam193$7,309
Rufinamide12$6,591
Memantine Hcl183$6,005
Pregabalin95$5,510
Rasagiline Mesylate11$4,897
Oxcarbazepine58$4,697
Lamotrigine137$4,680

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
BiogenAvonex (4 Pack)$57$108,40514 claims
AbbVieUbrelvy, Qulipta$18,306$42,21636 claims
Upsher-smith Laboratories LLCTopiramate$30$1,859189 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,246 neurology providers in Texas.

Other neurology in Wichita Falls

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →